序贯无创检测提高肝纤维化筛查效率

摘要/Abstract

摘要： 进展期肝纤维化和肝硬化严重影响人民健康。近年来,随着医疗诊断技术的发展,肝病领域已开发出多种检查方法用于主动筛查肝纤维化患者,尤其非侵入性肝纤维化测试(non-invasive fibrosis tests,NIT)序贯检测(序贯无创检测)可逐步将晚期肝纤维化患者从高危人群中筛选出来。NIT序贯检测在降低医疗成本的同时,可有效减少不必要的转诊,进而可提高肝纤维化的筛查和诊疗效率并实现对肝纤维化患者的精准管理。本文概述了肝纤维化的筛查和诊断方法、NIT序贯检测的策略及其临床意义,以及近年报道的新型肝纤维化生物标志物,旨在为优化肝纤维化序贯无创检测的策略提供新思路,从而提高肝纤维化的筛查效率。

关键词: 肝纤维化, 非侵入性纤维化测试, 纤维化-4指数, 增强肝纤维化评分, 瞬时弹性成像

李雨蓉, 姚明解, 王杰. 序贯无创检测提高肝纤维化筛查效率[J]. 肝脏, 2023, 28(10): 1146-1148.

参考文献

[1] 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年版)[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2] Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023,165(4):1025-1040.
[3] Zhang YN, Fowler KJ, Ozturk A, et al. Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography[J]. J Magn Reson Imaging, 2020, 51(1): 25-42.
[4] Im WH, Song JS, Jang W. Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques[J]. Abdom Radiol, 2022, 47(9): 3051-3067.
[5] Li S, Sun X, Chen M, et al. Liver fibrosis conventional and molecular imaging diagnosis update[J]. J liver, 2019, 8(1): 236.
[6] Jayaswal ANA, Levick C, Selvaraj EA, et al. Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease[J]. Liver Int, 2020, 40(12): 3071-3082.
[7] Montesi SB, Désogère P, Fuchs BC, et al. Molecular imaging of fibrosis: recent advances and future directions[J]. J Clin Invest, 2019, 129(1): 24-33.
[8] Castera L. Non-invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics[J]. Liver Int, 2020, 40(S1): 77-81.
[9] Tsochatzis EA. Screening for liver fibrosis-sequential non-invasive testing works best[J]. J Hepatol, 2023, 79(2): 263-265.
[10] Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2019, 71(2): 371-378.
[11] Berzigotti A, Tsochatzis E, Boursier J, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update[J]. J Hepatol, 2021, 75(3): 659-689.
[12] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[13] Kjaergaard M, Lindvig KP, Thorhauge KH, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease[J]. J Hepatol, 2023, 79(2): 277-286.
[14] Yao M, Wang L, Leung PSC, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review[J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294.
[15] Liu L, Al-Dhamin Z, Yuan X, et al. Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis[J]. Histol Histopathol, 2020, 35(11): 1309-1318.
[16] Cao Z, Li Z, Wang H, et al. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection[J]. Liver Int, 2017, 37(11): 1612-1621.
[17] 姚明解, 王雷婕, 关贵文, 等. 血清高尔基体蛋白73在辅助诊断慢性乙型肝炎患者中度以上肝损伤中的应用[J]. 临床肝胆病杂志, 2018, 34(4): 755-759.
[18] Smirne C, Rigamonti C, De Benedittis C, et al. Gas6/TAM signaling components as novel biomarkers of liver fibrosis[J]. Dis Markers, 2019, 2019: e2304931.
[19] Caussy C, Chuang JC, Billin A, et al. Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis[J]. Ther Adv Gastroenterol, 2020, 13: 1756284820923904.
[20] Kozumi K, Kodama T, Murai H, et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis[J]. Hepatology, 2021, 74(5): 2452-2466.